Compounded tirzepatide for obesity

Obesity: what it is

Obesity is a chronic disease defined by excess body fat that increases the risk of cardiovascular disease, type 2 diabetes, and other comorbidities. The American Medical Association recognized obesity as a disease in 2013. Standard threshold: BMI ≥30 (or ≥27 with a weight-related condition).

How Compounded tirzepatide fits into obesity treatment

First-line: lifestyle modification (calorie deficit, structured physical activity, behavioral counseling). Pharmacotherapy is indicated for BMI ≥30 or ≥27 with comorbidity. GLP-1 receptor agonists (semaglutide/Wegovy, liraglutide/Saxenda) and the dual GLP-1/GIP agonist tirzepatide (Zepbound) are now first-line drug therapy due to 14-22% mean body-weight reduction in trials. Older agents (phentermine, naltrexone-bupropion, orlistat) remain options. Bariatric surgery for BMI ≥40 or ≥35 with severe comorbidity.

Compounded tirzepatide works by: Pharmacologically identical to branded tirzepatide. Dual GLP-1/GIP receptor agonist.

Who qualifies for Compounded tirzepatide for obesity

Same eligibility as branded tirzepatide.

Off-label note: Compounded tirzepatide is not FDA-approved for obesity. Off-label prescribing is legal and clinically appropriate when supported by evidence and shared clinical decision-making. Insurance coverage for off-label use is often more difficult than for labeled indications — expect prior-authorization challenges and stronger documentation requirements.

How Compounded tirzepatide compares to other obesity treatments

• Wegovy for obesity

  Once-weekly injectable semaglutide for chronic weight management. ~15% body weight loss in trials.…

• Zepbound for obesity

  Dual GLP-1/GIP agonist for weight management. ~20% body weight loss in trials — strongest weight-loss drug cur…

• Saxenda for obesity

  FDA-approved daily injectable liraglutide for chronic weight management. Older-generation GLP-1, daily dosing.…

• Compounded semaglutide for obesity

  Custom-compounded semaglutide. Cheaper than branded Wegovy. Not FDA-approved; legal landscape shifts.…

Frequently asked about obesity

Is obesity considered a disease?

Yes. The American Medical Association formally recognized obesity as a disease in 2013, and the World Health Organization classifies it as a chronic condition. This framing matters clinically (it justifies long-term treatment) and financially (it supports insurance coverage of pharmacotherapy).

How much weight loss is clinically meaningful?

5-10% body-weight reduction sustained for 6+ months produces measurable improvement in blood pressure, lipids, glucose control, and quality of life. GLP-1 trials produce 14-22% mean weight loss — well above the threshold for clinical benefit.

Do I need to fail diet and exercise before getting a GLP-1?

Clinical guidelines no longer require documented failure of lifestyle intervention before initiating pharmacotherapy if BMI criteria are met. Many insurance plans, however, do require documented prior attempts. A program with an insurance concierge handles this paperwork for you.

Will I have to take a GLP-1 forever?

Trial extension data shows roughly two-thirds of lost weight returns within 12-18 months of discontinuation. The clinical model is chronic-disease treatment, similar to managing hypertension or hyperlipidemia. Some patients move to a lower maintenance dose rather than a full stop.